Cargando…

The clinical characteristics and prognostic analysis of Chinese advanced NSCLC patients based on circulating tumor DNA sequencing

PURPOSE: Circulating tumor DNA (ctDNA) is a noninvasive and real-time marker for tumor diagnosis, prognosis, and prediction. However, further investigations about ctDNA prognostic and predictive value are still needed, and conclusions from several studies were inconsistent. EXPERIMENTAL DESIGN: We p...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rao, Chuangzhou, Nie, Liangqin, Miao, Xiaobo, Xu, Yunbao, Li, Bing, Zhang, Tengfei
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2018
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5769570/ https://www.ncbi.nlm.nih.gov/pubmed/29391810 http://dx.doi.org/10.2147/OTT.S154589

Ejemplares similares

Targeted sequencing identifies the mutational signature of double primary and metastatic malignancies: a case report
por: Rao, Chuangzhou, et al.
Publicado: (2019)

Case report: Durable response to alectinib in ALK-rearranged lung adenocarcinoma with acquired, crizotinib-resistant ALK C1156F mutation
por: Rao, Chuangzhou, et al.
Publicado: (2022)

Prognostic Value of Circulating Tumor DNA (ctDNA) in Oncogene-Driven NSCLC: Current Knowledge and Future Perspectives
por: Zografos, Eleni, et al.
Publicado: (2022)

Circulating Tumor DNA correlates with Lactate Dehydrogenase, CYFRA 21-1, and CRP levels in patients with advanced NSCLC
por: Buresova, Marcela, et al.
Publicado: (2023)

Prognostic value of plasma EGFR ctDNA in NSCLC patients treated with EGFR-TKIs
por: Zhang, Chengjuan, et al.
Publicado: (2017)

OPRM1-ROS1 Fusion Detected by Next-Generation Sequencing with Circulating DNA in a Patient with EGFR Mutated Advanced NSCLC: A Case Report
por: Zhang, Sicai, et al.
Publicado: (2022)

The value of cell-free circulating tumour DNA profiling in advanced non-small cell lung cancer (NSCLC) management
por: Fernandes, Maria Gabriela O., et al.
Publicado: (2021)

Circulating DNA: Diagnostic Tool and Predictive Marker for Overall Survival of NSCLC Patients
por: Catarino, Raquel, et al.
Publicado: (2012)

Rescue of Non-Informative Circulating Tumor DNA to Monitor the Mutational Landscape in NSCLC
por: Mayer, Stefanie, et al.
Publicado: (2020)

Cerebrospinal fluid circulating tumor DNA depicts profiling of brain metastasis in NSCLC
por: Wu, Jun, et al.
Publicado: (2022)

Dynamic monitoring of circulating tumor DNA to analyze genetic characteristics and resistance profile of lorlatinib in ALK positive previously treated NSCLC
por: Ma, Xiya, et al.
Publicado: (2023)

Benefit packages for chronic disease outpatients in the New Rural Cooperative Medical Scheme in 32 Chinese counties
por: Xu, Chuangzhou, et al.
Publicado: (2013)

The Genomic Characteristics of ALK Fusion Positive Tumors in Chinese NSCLC Patients
por: Liu, Shaokun, et al.
Publicado: (2020)

Circulating PD-L1 in NSCLC patients and the correlation between the level of PD-L1 expression and the clinical characteristics
por: Zhang, Jie, et al.
Publicado: (2015)

Dynamic changes in circulating tumor DNA assessed by shallow whole‐genome sequencing associate with clinical efficacy of checkpoint inhibitors in NSCLC
por: Carbonell, Caterina, et al.
Publicado: (2023)

EGFR mutation analysis on circulating free DNA in NSCLC: a single-center experience
por: Ianza, Anna, et al.
Publicado: (2021)

Early circulating tumor DNA dynamics at the commencement of curative-intent radiotherapy or chemoradiotherapy for NSCLC
por: MacManus, Michael, et al.
Publicado: (2023)

LncRNA FOXD3-AS1 promoted chemo-resistance of NSCLC cells via directly acting on miR-127-3p/MDM2 axis
por: Zeng, Zhaolong, et al.
Publicado: (2020)

Evaluation of Circulating Tumor Cells and Related Events as Prognostic Factors and Surrogate Biomarkers in Advanced NSCLC Patients Receiving First-Line Systemic Treatment
por: Muinelo-Romay, Laura, et al.
Publicado: (2014)

Immunotherapeutic Advances for NSCLC
por: Massafra, Marco, et al.
Publicado: (2021)

Circulating Biomarkers for Prediction of Immunotherapy Response in NSCLC
por: Goh, Kah Yee, et al.
Publicado: (2023)

FOXP family DNA methylation correlates with immune infiltration and prognostic value in NSCLC
por: Hu, Dong-Mei, et al.
Publicado: (2022)

The BIM deletion polymorphism is a prognostic biomarker of EGFR-TKIs response in NSCLC: A systematic review and meta-analysis
por: Nie, Wei, et al.
Publicado: (2015)

Characteristics of and Treatment Strategies for Advanced EGFR-Mutant NSCLC With Concomitant BRAF Variations
por: Wei, Xue-Wu, et al.
Publicado: (2022)

In-depth circulating tumor DNA sequencing for prognostication and monitoring in natural killer/T-cell lymphomas
por: Kim, Jin Ju, et al.
Publicado: (2023)

Molecular and clinical characteristics of IDH mutations in Chinese NSCLC patients and potential treatment strategies
por: Chen, Shuchen, et al.
Publicado: (2022)

Levels of pretreatment blood lipids are prognostic factors in advanced NSCLC patients treated with anlotinib
por: Tang, Mengqiu, et al.
Publicado: (2021)

Prognostic effect of body mass index in patients with advanced NSCLC treated with chemoimmunotherapy combinations
por: Cortellini, Alessio, et al.
Publicado: (2022)

Updated Prognostic Factors in Localized NSCLC
por: Garinet, Simon, et al.
Publicado: (2022)

Circulating Ang-2 mRNA Expression Levels: Looking Ahead to a New Prognostic Factor for NSCLC
por: Coelho, Ana L., et al.
Publicado: (2014)

Correction: Circulating Ang-2 Mrna Expression Levels: Looking ahead to a New Prognostic Factor for NSCLC
Publicado: (2014)

Diagnostic and Prognostic Characteristics of Circulating Free DNA Methylation Detected by the Electrochemical Method in Malignant Tumors
por: Sun, Li-Yue, et al.
Publicado: (2021)

Circulating CD81-expressing extracellular vesicles as biomarkers of response for immune-checkpoint inhibitors in advanced NSCLC
por: Signorelli, Diego, et al.
Publicado: (2022)

Circulating Plasma MicroRNAs As Diagnostic Markers for NSCLC
por: Hou, Jinpao, et al.
Publicado: (2016)

Real‐world outcomes of NSCLC patients receiving tissue or circulating tumor DNA‐guided osimertinib treatment
por: Su, Po‐Lan, et al.
Publicado: (2019)

Feasibility of next‐generation sequencing test for patients with advanced NSCLC in clinical practice
por: Ariyasu, Ryo, et al.
Publicado: (2020)

Review of the clinical applications and technological advances of circulating tumor DNA in cancer monitoring
por: Chang, Yi, et al.
Publicado: (2017)

Therapeutic Sequencing in ALK(+) NSCLC
por: Elsayed, Mei, et al.
Publicado: (2021)

Differences in the genomic profiles of cell‐free DNA between plasma, sputum, urine, and tumor tissue in advanced NSCLC
por: Wu, Zhen, et al.
Publicado: (2019)

Ultra-Short Circulating Tumor DNA (usctDNA) in Plasma and Saliva of Non-Small Cell Lung Cancer (NSCLC) Patients
por: Li, Feng, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_16j7j1aafocejdpqclmqhhq3nk